RxDoctor Payments DataLook up a doctor →

Chad Metzger, DO

Interventional Pain Medicine · Darby, PANPI 1184074783

Payments from drug & device makers

$14,339in general payments, 2019–2025

Across 409 payments — averaging $35.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$3K
  • Abbott$3K
  • MML US, Inc.$2K
  • Boston Scientific$2K
  • Nevro Corp.$875
  • Vertos Medical, Inc.$764
  • plus $3K from 27 others

What the payments were for

  • Travel & lodging$3,70126%
  • Food & beverage$10,63874%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,339 in reported general payments places this provider in the 85th percentile of 59 interventional pain medicine providers in Pennsylvania.

See all interventional pain medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$505,196
Medicare patients
409
Services billed
10,234

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl22$19,472
Hysingla ErHydrocodone Bitartrate17$12,063
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen492$11,586
Oxycodone Hcl558$10,985
Morphine Sulfate ErMorphine Sulfate211$9,300
MovantikNaloxegol Oxalate20$8,955
Oxymorphone Hcl ErOxymorphone Hcl12$7,888
Butorphanol Tartrate14$7,856
Gabapentin509$4,590
EndocetOxycodone Hcl/Acetaminophen37$2,975
Pregabalin237$2,539
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen174$2,519
Lidocaine36$2,300
Tizanidine Hcl248$2,282
Tramadol Hcl248$2,186

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca$445$19,47222 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 59 interventional pain medicine providers in Pennsylvania.

Other interventional pain medicine in Darby

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →